Investment Focus
Artificial Intelligence
Digital Media
3D Printing
eCommerce
Autonomous Technology
Biotech
Overview
- Type: Index Equity
- Typical # of Holdings: 35-45
- Inception: Sept. 2017
- Portfolio Manager: Catherine Wood
- Analyst: Collective Team
Strategy Description
This index-based equity strategy seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the ARK Israeli Innovation Index, which is designed to track the price movements of exchange-listed Israeli companies whose main business operations are causing disruptive innovation in the areas of genomics, health care, biotechnology, industrials, manufacturing, the Internet or information technology. The Index includes equity securities and depositary receipts of exchange listed companies that are incorporated and/or domiciled in Israel (‘‘Israeli Companies’’) and are included in one of the following economic sectors as defined by FactSet Research Systems: (i) health technology, (ii) communications, (iii) technology services, (iv) electronic technology, (v) consumer services, or (vi) producer manufacturing.
Availability
Strategy | ETF | Managed Account |
---|---|---|
ARK Israel Innovative Technology |
The content presented does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. Certain of the statements contained on this website may be statements of future expectations and other forward-looking statements that are based on ARK’s current views and assumptions, and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that ARK’s objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors. For full disclosures, please go to our Terms & Conditions page.
Targeted Exposure to Israeli Innovation
Equal market capitalization weighting
Investment Team
Catherine Wood
Chief Executive Officer
Chief Investment Officer
Catherine Wood
Chief Executive Officer
Chief Investment Officer
Articles from Catherine Wood:
See all articlesInnovation Stocks Are Not in A Bubble: We Believe They Are in Deep Value Territory
The Rotation From Growth Into Value Stocks Has Strengthened This Bull Market
Brett Winton
Director of Research
Brett Winton
Director of Research
Articles from Brett Winton:
See all articlesWill Innovation Investing Help Achieve the UN Sustainable Development Goals?
Tasha Keeney, CFA
Analyst
Tasha Keeney, CFA
Analyst
Articles from Tasha Keeney, CFA:
See all articlesARK’s Price Target for Tesla in 2025
Renato Leggi, CFA, CAIA
Client Portfolio Manager
Renato Leggi, CFA, CAIA
Client Portfolio Manager
Articles from Renato Leggi, CFA, CAIA:
See all articlesThe Equity Market Cap Associated with Technologically Enabled Innovation Is Likely to Grow Exponentially
Strategic Allocation To Innovation: A Comparison to Emerging Markets
We believe a strategic allocation to innovation probably will evolve into a sub-asset class, as did the “niche” strategy of the 1980s—emerging markets.
Simon Barnett
Analyst
Simon Barnett
Analyst
Articles from Simon Barnett:
See all articlesThe Exploitable Genomics of Cancer: Earlier Cancer Detection Part II
The Genomics Age of Cancer Screening: Earlier Cancer Detection
Alexandra Urman
Analyst
Alexandra Urman
Analyst
Articles from Alexandra Urman:
See all articlesTechnology Could Boost the NPV of Biopharmaceutical Pipeline Assets Significantly
Yassine Elmandjra
Analyst
Yassine Elmandjra
Analyst
Articles from Yassine Elmandjra:
See all articlesNicholas Grous
Analyst
Nicholas Grous
Analyst